+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 22Years +
All Genders
ID07868068

Evaluating the HemoPill Acute Device for Detecting Blood in the Upper Gastrointestinal Tract Compared to Endoscopy

Led by Stony Brook University · Updated on 2026-10-09

50

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

This clinical trial investigates whether the HemoPill acute device can detect blood in people suspected of having upper gastrointestinal GI bleeding. The study aims to understand how the HemoPill acute compares to the standard endoscopy procedure in identifying blood or bleeding in the upper GI tract. It focuses on the diagnostic relationship between these two methods to improve detection accuracy. Participants will swallow the HemoPill acute device between one to four hours before their scheduled endoscopy, which is part of their standard care. They will keep the device receiver close to their body from ingestion until the endoscopy is completed. Afterward, participants will return for follow-up visits to confirm whether the device has passed and to report any adverse events. During the study, researchers will assess how well the device detects blood by comparing it to endoscopy results. They will also monitor the devices transit and excretion, technical performance, and any safety concerns up to 21 days after swallowing the device. Participants will be closely monitored through follow-up visits to ensure their safety and gather all necessary data.

CONDITIONS

Brief Title

Detection of Blood in the GI Lumen With HemoPill Acute

Research Team

J

Joseph LaComb

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here